No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NNVC240517C2500
- 0.05
- -0.05-50.00%
15min DelayTrading May 14 13:29 ET
0.15High0.05Low
0.10Open0.10Pre Close184 Volume545 Open Interest2.50Strike Price1.82KTurnover182.63%IV18.61%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.2400Delta0.8071Gamma43.00Leverage Ratio-0.0178Theta0.0000Rho10.32Eff Leverage0.0007Vega
Intraday
- 5D
- 1D
News
NYSE American New 52-Week Highs And Lows
New Highs 5 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Actinium Pharmaceuticals ATNM 9.99 307,312 Am
A Novel Broad-Spectrum Antiviral With Activity Against RSV
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. , a global
NanoViricides Unveils New Data Showing Lead Drug Asset's Strong Activity Against RSV | NYSE-A:NNVC
NanoViricides CEO Discusses NV-387's Broad-spectrum Antiviral Potential | NYSE-A:NNVC
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. , a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's
NanoViricides to Showcase Lead Drug Asset's Progress at EF Hutton Annual Global Conference | NYSE-A:NNVC
Comments
$Nanoviricides(NNVC.US$
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
1
$Scynexis(SCYX.US$
$Nanoviricides(NNVC.US$
$Tenet Healthcare(THC.US$
I want to watch these the most, I think, and now to find stuff in a different sector..
$Nanoviricides(NNVC.US$
$Tenet Healthcare(THC.US$
I want to watch these the most, I think, and now to find stuff in a different sector..
1
$Nanoviricides(NNVC.US$
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides, Inc. announces NV-387, a novel broad-spectrum antiviral with activity against Smallpox/Mpox. NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox, both inhalation and skin abrasion modes. Animal studies demonstrate increased survival compared to tecovirimat, approved for Smallpox. NV-387 potentially reduces tecovirimat resistance. NanoViricides focuses on developing antiv...
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides, Inc. announces NV-387, a novel broad-spectrum antiviral with activity against Smallpox/Mpox. NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox, both inhalation and skin abrasion modes. Animal studies demonstrate increased survival compared to tecovirimat, approved for Smallpox. NV-387 potentially reduces tecovirimat resistance. NanoViricides focuses on developing antiv...
1
$Nanoviricides(NNVC.US$ Reuters· 3 mins ago
NanoViricides Inc: Ultra-Broad Antiviral Activity Spectrum of NV-387 Includes Influenza a Viruses, Possibly Including Bird Flu H5N1 Virus as Well! NanoViricides: Anti-Influenza Activity of NV-387 Given Orally Substantially Superior to All 3 Approved Anti-Influenza Drugs
NanoViricides Inc: Ultra-Broad Antiviral Activity Spectrum of NV-387 Includes Influenza a Viruses, Possibly Including Bird Flu H5N1 Virus as Well! NanoViricides: Anti-Influenza Activity of NV-387 Given Orally Substantially Superior to All 3 Approved Anti-Influenza Drugs
$Nanoviricides(NNVC.US$ NanoViricides Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon
Accesswire· 3 mins ago
Accesswire· 3 mins ago
1
Read more